Back to Search
Start Over
Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
- Source :
-
PloS one [PLoS One] 2014 Dec 01; Vol. 9 (12), pp. e114006. Date of Electronic Publication: 2014 Dec 01 (Print Publication: 2014). - Publication Year :
- 2014
-
Abstract
- Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10-20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund's adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40% of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBc-derived virus-like particles as the biological component.
- Subjects :
- Adjuvants, Immunologic chemistry
Alum Compounds pharmacology
Animals
Female
Freund's Adjuvant immunology
Freund's Adjuvant pharmacology
Hepatitis B immunology
Hepatitis B Core Antigens immunology
Hepatitis B Vaccines immunology
Immunity, Humoral drug effects
Immunization
Lipid A analogs & derivatives
Lipid A immunology
Lipid A pharmacology
Lipids immunology
Lipids pharmacology
Mice, Inbred BALB C
Nanoparticles chemistry
Silicon Dioxide chemistry
Silicon Dioxide immunology
Adjuvants, Immunologic pharmacology
Hepatitis B prevention & control
Hepatitis B Core Antigens pharmacology
Hepatitis B Vaccines pharmacology
Hepatitis B virus immunology
Silicon Dioxide pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 9
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 25436773
- Full Text :
- https://doi.org/10.1371/journal.pone.0114006